Cargando…

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

To date, belimumab is the only biological drug approved for the treatment of patients with active refractory SLE. We compared and critically analyzed the results of 11 observational clinical-practice-based studies, conducted in SLE referral centers. Despite the differences in endpoints and follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trentin, Francesca, Gatto, Mariele, Zen, Margherita, Maddalena, Larosa, Nalotto, Linda, Saccon, Francesca, Zanatta, Elisabetta, Iaccarino, Luca, Doria, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132773/ https://www.ncbi.nlm.nih.gov/pubmed/29512034 http://dx.doi.org/10.1007/s12016-018-8675-2

Ejemplares similares

Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies
por: Trentin, Francesca, et al.
Publicado: (2018)

Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
por: Zen, Margherita, et al.
Publicado: (2023)

Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
por: Ghirardello, Anna, et al.
Publicado: (2023)

Effect of pregnancy on serum cytokines in SLE patients
por: Doria, Andrea, et al.
Publicado: (2012)

Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
por: Gatto, Mariele, et al.
Publicado: (2022)

SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy
por: Larosa, Maddalena, et al.
Publicado: (2021)

Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease
por: Franco, Chiara, et al.
Publicado: (2023)

CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease
por: Villalta, Danilo, et al.
Publicado: (2013)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management
por: De Zorzi, Elena, et al.
Publicado: (2022)

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
por: D'Cruz, David, et al.
Publicado: (2023)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
por: Bruce, I N, et al.
Publicado: (2016)

Drugs in induction and treatment of idiopathic inflammatory myopathies
por: Iaccarino, Luca, et al.
Publicado: (2014)

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients
por: Escalera, Carlos Rodríguez, et al.
Publicado: (2022)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

PReS-FINAL-2285: Pediatric non-renal SLE presenting as periorbital edema: response to treatment with belimumab
por: Arabshahi, B
Publicado: (2013)

Protective molecules and their cognate antibodies: new players in autoimmunity
por: Zen, Margherita, et al.
Publicado: (2010)

SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients
por: Zen, M., et al.
Publicado: (2020)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE
por: Struemper, Herbert, et al.
Publicado: (2022)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
por: Arvaniti, Pinelopi, et al.
Publicado: (2020)

SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype
por: Gatto, Mariele, et al.
Publicado: (2018)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review
por: Depascale, Roberto, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis
por: Birt, Julie A, et al.
Publicado: (2020)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019)

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study
por: Bae, Sang-Cheol, et al.
Publicado: (2022)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

B Cell Tolerance and Targeted Therapies in SLE
por: Parodis, Ioannis, et al.
Publicado: (2023)

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020)

Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis
por: Rahmé, Zahrà, et al.
Publicado: (2023)

Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort
por: Zanatta, Elisabetta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qbagj2b4jupfnqvulgknjih79r